{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:20:51Z","timestamp":1773404451128,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Following recognition that blood, blood components, tissues and organs donated by infected donors could transmit infectious prions causing variant Creutzfeldt\u2010Jakob Disease (vCJD), several risk reduction measures were introduced in the UK. The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) established a working group to review the measures in place. Factors considered included: ethical issues around the current provisions and potential changes; operational issues for blood establishments and hospitals; a review from the Advisory Committee on Dangerous Pathogens (ACDP) showing the downward trend in the estimated number of future cases of vCJD; and cost\u2010effectiveness. The working group recommended that the current vCJD risk reduction measures for individuals born after 1995 or with thrombotic thrombocytopenic purpura (TTP) could be withdrawn. After consultation with stakeholders, SaBTO accepted these proposals which allow more equal provision of components, less operational complexity and risk, and more resources to be deployed elsewhere in the NHS. The potential saving on plasma will be \u00a3500\u2009m and moving to using pooled platelets in additive solution for all recipients will bring potential savings of \u00a3280\u2009m over the next 50 to 60\u2009years. There could be small number of additional clinical cases of vCJD: 1\u20132 (&lt;1\u201314; 95% CI) from plasma and 3\u20134 (&lt;1 to 45; 95% CI) from platelets. Local and national guidelines will still be applied for managing individual conditions. UK Ministers for Health accepted SaBTO's recommendations on 9 Sept 2019 and implementation began immediately. This paper describes the review and rationale leading to these recommendations.<\/jats:p>","DOI":"10.1111\/tme.12840","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T08:14:46Z","timestamp":1638864886000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Importation of plasma and use of apheresis platelets as risk reduction measures for variant <scp>Creutzfeldt\u2010Jakob<\/scp> disease: The <scp>SaBTO<\/scp> review"],"prefix":"10.1111","volume":"32","author":[{"given":"Stephen","family":"Thomas","sequence":"first","affiliation":[{"name":"NHS Blood and Transplant  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Health and Social Care  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Marie","family":"Slowther","sequence":"additional","affiliation":[{"name":"Warwick Medical School Division of Health Sciences, Gibbet Hill Campus  Coventry UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Coelho","sequence":"additional","affiliation":[{"name":"Department of Health and Social Care  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-4934","authenticated-orcid":false,"given":"Gary","family":"Mallinson","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant  Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Paediatric Components Working Group of the Advisory Committee on the Safety of Blood, Tissues and Organs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Food Standards Agency.Bovine Spongiform Encephalopathy (BSE).2021. Accessed March 15 2021.https:\/\/www.food.gov.uk\/safety-hygiene\/bovine-spongiform-encephalopathy-bse."},{"key":"e_1_2_9_3_1","unstructured":"The National CJD Research & Surveillance Unit (NCJDRSU).2021. Accessed March 15 2021.https:\/\/www.cjd.ed.ac.uk\/."},{"key":"e_1_2_9_4_1","volume-title":"Guidelines for the Blood Transfusion Services in the UK","author":"Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee","year":"2021"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09167.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_9_7_1","volume-title":"vCJD Transmission by Blood Components: Risk Assessment","author":"GOV.UK","year":"2021"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023169"},{"key":"e_1_2_9_9_1","volume-title":"Advisory Committee on Dangerous Pathogens","author":"GOV.UK","year":"2021"},{"key":"e_1_2_9_10_1","unstructured":"Alliance of Blood Operators.Risk Based Decision Making. Accessed March 16 2021.https:\/\/www.allianceofbloodoperators.org\/abo-resources\/risk-based-decision-making.aspx"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/0272-4332.00001"},{"key":"e_1_2_9_12_1","unstructured":"Infected Blood Inquiry. Accessed May 13 2021.https:\/\/www.infectedbloodinquiry.org.uk\/"},{"key":"e_1_2_9_13_1","unstructured":"British National Formulary \u2010 NICE.Fresh Frozen Plasma. Accessed May 14 2021.https:\/\/bnf.nice.org.uk\/medicinal-forms\/fresh-frozen-plasma.html"},{"key":"e_1_2_9_14_1","unstructured":"British National Formulary \u2010 NICE.Fibrinogen Dried. Accessed March 15 2021.https:\/\/bnf.nice.org.uk\/drug\/fibrinogen-dried.html"},{"key":"e_1_2_9_15_1","unstructured":"The Public Contracts Regulations 2015. Accessed March 15 2021.https:\/\/www.legislation.gov.uk\/uksi\/2015\/102\/contents\/made"},{"key":"e_1_2_9_16_1","volume-title":"Importation of Plasma as a VCJD Risk Reduction Measure","author":"Parker A","year":"2021"},{"key":"e_1_2_9_17_1","unstructured":"Joint Professional Advisory Committee.Change Notification 23\u20102020.2021. Accessed March 15 2021.https:\/\/www.transfusionguidelines.org\/red-book\/change-notifications."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14233"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12327"},{"key":"e_1_2_9_20_1","unstructured":"Serious Hazards of Transfusion.2021. Accessed March 15 2021.https:\/\/www.shotuk.org\/."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13642"},{"key":"e_1_2_9_22_1","volume-title":"Risk reduction measures for variant Creutzfeldt\u2010Jakob disease: PCWG report","author":"SaBTO","year":"2021"},{"key":"e_1_2_9_23_1","unstructured":"Written statements\u2014Written questions answers and statements\u2014UK Parliament.2021. Accessed March 15 2021.https:\/\/questions-statements.parliament.uk\/written-statements\/detail\/2019-09-09\/hcws1821"},{"key":"e_1_2_9_24_1","unstructured":"Transfusion for Fetuses Neonates and Older Children. British Society for Haematology.https:\/\/b-s-h.org.uk\/guidelines\/guidelines\/transfusion-for-fetuses-neonates-and-older-children\/."}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tme.12840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:55:46Z","timestamp":1693212946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/tme.12840"],"URL":"https:\/\/doi.org\/10.1111\/tme.12840","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"2021-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}